"There is no evidence that these supplements actually work, and we really don't know how they work as they have not been rigorously studied nor FDA-approved," she tells Yahoo Life
If you are a healthcare provider helping patients access these medications, understanding Medicaid coverage is essential to running an effective weight loss practice
Sathyapalan (Eds.), Natural products and human diseases: pharmacology, molecular targets, and therapeutic benefits (pp
however, they should be reserved for inadequate weight loss despite implementing lifestyle interventions, according to the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) 2016 clinical practice guideline
Morgan Research forecasts that the GLP-1 market will exceed $100 bn by 2030, driven equally by diabetes and obesity usage
However, people with MS who also have obesity or type 2 diabetes may be candidates for GLP-1 therapy, says Alan David Kaye, MD, PhD, a professor and the vice chair of research in the anesthesiology department at LSU Health in Shreveport, Louisiana
